Anti-inflammatory effect of the spirocyclopiperazinium compound LXM-10 in mice and rats

European Journal of Pharmacology

Volumn 626, Issue 2-3, 2010, Pages 290-296

  Xiong, Yulan ^a,c   Ye, Jia ^a,b   Sun, Qi ^b   Zhao, Xia ^b   Li, Runtao ^b   Jiang, Yimin ^a  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c PEKING UNIVERSITY SIXTH HOSPITAL   (China)

Author keywords

7 nicotinic acetylcholine receptor; Anti inflammation; LXM 10; M4 muscarine acetylcholine receptor

Indexed keywords

2,4 DIMETHYL 9 BETA PHENYLETHYL 3 OXO 6,9 DIAZASPIRO[5,5]UNDECANE CHLORIDE; ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIINFLAMMATORY AGENT; ASPARTATE AMINOTRANSFERASE; ATROPINE METHYL NITRATE; BUNGAROTOXIN RECEPTOR; CARRAGEENAN; DEXAMETHASONE; HEXAMETHONIUM; LIPOPOLYSACCHARIDE; METHYLLYCACONITINE; MUSCARINIC M4 RECEPTOR; PROSTAGLANDIN E2; TROPICAMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; XYLENE;

ACUTE TOXICITY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; DRUG POTENTIATION; DRUG STRUCTURE; EDEMA; ENZYME ACTIVITY; FEMALE; HEART RATE; HISTOLOGY; IMMUNOPHARMACOLOGY; LD 50; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ASPARTATE AMINOTRANSFERASES; DINOPROSTONE; FEMALE; HEART RATE; INFLAMMATION; MALE; MICE; PIPERAZINES; RATS; RECEPTORS, MUSCARINIC; RECEPTORS, NICOTINIC; SPIRO COMPOUNDS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70649106816     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.10.003     Document Type: Article

References (32)

1. Beirith A., Santos A.R., Rodrigues A.L., Creczynski-Pasa T.B., and Calixto J.B. Spinal and supraspinal antinociceptive action of dipyrone in formalin, capsaicin and glutamate tests. Study of the mechanism of action. Eur. J. Pharmacol. 345 (1998) 233-245
2. Bernik T.R., Friedman S.G., Ochani M., DiRaimo R., Ulloa L., Yang H., Sudan S., Czura C.J., Ivanova S.M., and Tracey K.J. Pharmacological stimulation of the cholinergic antiinflammatory pathway. J. Exp. Med. 195 (2002) 781-788
3. Beutler B. TNF, immunity and inflammatory disease: lessons of the past decade. J. Invest. Med. 43 (1995) 227-235
4. Boccia M.M., Acosta G.B., and Baratti C.M. Memory improving actions of gabapentin in mice: possible involvement of central muscarinic cholinergic mechanism. Neurosci. Lett. 311 (2001) 153-156
5. Borovikova L.V., Ivanova S., Zhang M., Yang H., Botchkina G.I., Watkins L.R., Wang H., Abumrad N., Eaton J.W., and Tracey K.J. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405 (2000) 458-461
6. Caulfield M.P. Muscarinic receptors characterization, coupling and function. Pharmacol. Ther. 58 (1993) 319-379
7. Choi S., Choi H.H., Lee S.H., Ko S.H., You H.J., Ye S.K., and Chung M.H. TNF anti-inflammatory effects of 8-hydroxy-2′-deoxyguanosine on lipopolysaccharide-induced inflammation via Rac suppression in Balb/c mice. Free. Radical. Bio. Med. 12 (2007) 1594-1603
8. Davies N.M., Saleh J.Y., and Skjodt N.M. Detection and prevention of NSAID-induced enteropathy. J. Pharm. Pharm. Sci. 3 (2000) 137-155
9. Davis S.R. The therapeutic use of androgens in women. J. Biochem. Mol. Toxicol. 69 (1999) 177-184
10. Decker M.W., Buckley M.J., and Brioni J.D. Differential effects of pretreatment with nicotine and lobeline on nicotine-induced changes in body temperature and locomotor activity in mice. Drug Dev. Res. 31 (1994) 52-58
11. Decker M.W., Lin N.H., Wasicak J.T., Williams M., and Arneric S.P. Antinociceptive effects of the novel neuronal nicotinic acetylcholine receptor agonist, ABT-594, in mice. Eur. J. Pharmacol. 346 (1998) 23-33
12. Duttaroy A., Gomeza J., Gan J.W., Siddiqui N., Basile A.S., Harman W.D., Smith P.L., Felder C.C., Levey A.I., and Wess J. Evaluation of muscarinic agonist-induced analgesia in muscarinic acetylcholine receptor knockout mice. Mol. Pharmacol. 62 (2002) 1084-1093
13. Eglen R.M. Muscarinic receptor subtype pharmacology and physiology. Prog. Med. Chem. 43 (2005) 105-136
14. Gallowitsch-Puerta M., and Pavlov V.A. Neuro-immune interactions via the cholinergic anti-inflammatory pathway Margot. Life Sci. 80 (2007) 2325-2329
15. 2 receptors, and cyclic AMP-protein kinase A signaling. Mol. Pharmacol. 66 (2004) 337-346
16. Habashy R.R., Abdel-Naim A.B., Khalifa A.E., and Al-Azizi M.M. Anti-inflammatory effects of jojoba liquid wax in experimental models. Pharmacol. Res. 51 (2005) 95-105
17. James M.W., and Hawkey C.J. Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract. Brit. J. Clin. Pharmacol. 56 (2003) 146-155
18. Miyazawa A., Fujiyoshi Y., and Unwin N. Structure and gating mechanism of the acetylcholine receptor pore. Nature 423 (2003) 949-955
19. Nantel F., Denis D., Gordon R., Northey A., Cirino M., Metters K.M., and Chan C.C. Distribution and regulation of cyclooxygenase-2 in carrageenin-induced inflammation. Br. J. Pharmacol. 128 (1999) 853-859
20. Nishikori T., Irie K., Suganuma T., Ozaki M., and Yoshioka T. Anti-inflammatory potency of FR167653, a p38 mitogen-activated protein kinase inhibitor, in mouse models of acute inflammation. Eur. J. Pharmacol. 451 (2002) 327-333
21. 2 production and bone resorption in mouse calvarial bone cells. Int. J. Biochem. 36 (2004) 2270-2280
22. Pavlov V.A., and Tracey K.J. Neural regulators of innate immune responses and inflammation. Cell. Mol. Life Sci. 61 (2004) 2322-2331
23. Pavlov V.A., Ochani M., Gallowitsch-Puerta M., Ochani K., Huston J.M., Czura C.J., Al-Abed Y., and Tracey K.J. Central muscarinic cholinergic regulation of the systemic inflammatory response during endotoxemia. Proc. Natl. Acad. Sci. U.S.A. 103 (2005) 5219-5223
24. Subramanian B., Kuo F., Ada E., Kotyla T., Wilson T., Yoganathan S., and Nicolosi R. Enhancement of anti-inflammatory property of aspirin in mice by a nano-emulsion preparation. Int. Immunopharmacol. 8 (2008) 1533-1539
25. Van Westerloo D.J., Giebelen I.A., Florquin S., Bruno M.J., Larosa G.J., and Ulloa L. The vagus nerve and nicotinic receptors modulate experimental pancreatitis severity in mice. Gastroenterology 30 (2006) 1822-1830
26. Vogel H.G., and Vogel W.H. Drug Discovery and Evaluation. Pharmacological Assays (1997), Springer, Berlin 402-403
27. Wallace J.L. Selective cyclooxygenase-2 inhibitors: after the smoke has cleared. Digest Liver. Dis. 34 (2002) 89-94
28. Wang H., Yu M., Ochani M., Amella C.A., Tanovic M., Susarla S., Li J.H., Wang H., Yang H., Ulloa L., Al-Abed Y., Czura C.J., and Tracey K.J. Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation. Nature 421 (2003) 384-388
29. Wess J., Eglen R.M., and Gautam D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nature 6 (2007) 721-733
30. Winter C.A., Risley E.A., and Nuss G.W. Carrageenin-induced edema in hind paw of the rat as an assay for anti-inflammatory drug. Proc. Soc. Exp. Biol. Med. 111 (1962) 544-547
31. 2 receptor-GABAergic disinhibition pathway that modulates peripheral inflammation in mice. Neuropharmacology 53 (2007) 677-686
32. Yue C.Q., Ye J., Li C.L., Li R.T., and Sun Q. Antinociceptive effects of the novel spirocyclopiperazinium salt compound LXM-10 in mice. Pharmacol. Biochem. Behav. 6 (2007) 643-650